Bergen New Bridge Medical Center and NJ Reentry Corporation Launch ‘A New Bridge to Health’-A Complete Healthcare Program for Persons Leaving State Prisons

Virtual program will use telehealth to provide access to Medication Assisted Treatment (MAT) and healthcare providers

Paramus, NJ, Nov. 12, 2020 (GLOBE NEWSWIRE) — On Monday, November 16, 2020, Bergen New Bridge Medical Center and the NJ Reentry Corporation will implement an innovative program co-created called ‘A New Bridge to Health’. This new program links individuals being released from prison under the new COVID-19 early release bill with a prominent New Jersey health care provider that can offer immediate access to Medication-Assisted Treatment (MAT) for ongoing substance use disorder care. The program also offers connections to primary care providers, medication management, and treatment of chronic conditions via a telehealth platform.

“A New Bridge to Health” will offer Medication Assisted Treatment to those in substance use disorder care. NJRC participants will register in advance with NJRC personnel to schedule a telemedicine appointment with a physician. Many persons being released due to the pandemic have a limited two week supply of MAT. For many individuals released, their supply for MAT and other prescriptions will be exhausted as of Wednesday, November 18, 2020.

NJRC participants will complete intake process, providing MVC or NJDOC identification. Participants will be required to electronically sign to participate in treatments. The Bergen New Bridge Medical Center team will contact the participant at the respective NJRC site with an approved Bergen New Bridge IPAD. Clinical staff will conduct a health questionnaire screening with the participant to determine/schedule the appropriate medical provider.

“We are proud to work collaboratively with James McGreevey and the NJ Reentry Corporation to offer a complete continuum of care for those coming back to our communities,” said Deborah Visconi, President and CEO of Bergen New Bridge Medical Center. “Having an immediate connection to healthcare to maintain their medications and other conditions is crucial for successful reintegration after incarceration,” said Visconi. “This partnership aligns with our mission and dedication to caring for underserved populations, managing population health, and addressing social determinants of health to better care for our communities.”

“NJRC is greatly indebted to Bergen New Bridge Medical Center. Medication-Assisted Treatment is critically important for those addicted,” said James McGreevey, Chairman of New Jersey Recovery Corporation. “The medical and behavioral health care provided by Bergen New Bridge at our reentry sites will save lives.”

 “I could not be prouder of Deb and Bergen New Bridge and Jim and NJ Reentry for forging this partnership that will help acclimate those returning to their communities have the care they need to lead healthy and productive lives,” said James J. Tedesco, lll, Bergen County Executive. “Bergen New Bridge continues to be a community leader and the County asset and the work NJ Reentry is doing is life-changing. I appreciate the efforts of both organizations for our residents.”  

 # # #

 

 

ABOUT BERGEN NEW BRIDGE MEDICAL CENTER                                                                                                                     

Bergen New Bridge Medical Center (BNBMC), a clinical affiliate of Rutgers, is a 1,070-bed hospital located at 230 East Ridgewood Avenue in Paramus, NJ. The Medical Center is both the largest hospital and licensed nursing home in NJ and the fourth-largest publicly-owned hospital in the nation.

 

Bergen New Bridge Medical Center, a not-for-profit safety net facility, provides high-quality comprehensive services, including acute and ambulatory care from Rutgers New Jersey Medical School and community physicians, mental health and substance use disorder treatment, and long-term care to the greater Bergen County community. The Medical Center, including its Long-Term Care Division, is fully accredited by The Joint Commission and is in-network with all major New Jersey commercial insurance plans covering 99.91% of NJ residents.

Bergen New Bridge Medical Center is a full-service hospital with a 24/7 emergency department, surgical suites, physical rehabilitation, pharmacy, laboratory, radiologic services (including digital mammography), and more than 26 medical specialties available through its Ambulatory Care Center. The Medical Center is a Veterans Community Care Provider proudly serving the healthcare needs of veterans and is a Leader in LGBTQ Healthcare Equality in the Human Rights Campaign (HRC) Healthcare Equality Index (HEI) for 2020.  Learn more at www.newbridgehealth.org.

 

About the New Jersey Reentry Corporation

The New Jersey Reentry Corporation (NJRC) provides critically needed services to court-involved individuals, including persons having served the maximum sentence in state prison, state prison parolees, county jail probationers, Drug Court participants, and persons leaving federal prisons.

 

NJRC’s services include linking clients to addiction treatment (detoxification, residential treatment, intensive outpatient, outpatient, and providing Medication Assisted Treatment), structured sober housing, job training and employment, driver licenses restoration and legal services, and healthcare (medical, mental health, and behavioral).

 

Clients receive individualized clinical assessment and treatment plans that address essential health needs to become “work-ready.” NJRC’s pro bono legal services program screens and provides clients assistance with state identification and driver’s license restoration. NJRC then assists in securing employment for their clients with private and public employers who are “background-friendly.”

 

The New Jersey Reentry Corporation has 9,846 clients statewide with a rearrest rate of 19.7% and reincarceration rate of less than 10%, and an employment rate of 56.4-60.2% (adjusted seasonally). NJRC operates a statewide network of nine reentry sites in Bergen, Essex, Hudson, Middlesex, Monmouth, Ocean, Passaic, and Union Counties.

Donnalee Corrieri
Bergen New Bridge Medical Center 
2012257141
[email protected]

Maro Twal
NJ Reentry Corporation
201.993.7765
[email protected]

SHAREHOLDER DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against Wrap Technologies, Inc.– WRTC- PGEN, XON; IMPORTANT NOV. 23 DEADLINE- WRTC-

NEW YORK, Nov. 12, 2020 (GLOBE NEWSWIRE) — Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Wrap Technologies, Inc. (NASDAQ: WRTC) from April 29, 2020 through September 23, 2020, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Wrap Technologies, Inc. investors under the federal securities laws.

To join the class action, go here or call Vik Pawar, Esq. toll-free at 888-589-9804 or email [email protected] for information on the class action.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) the Company had concealed the results of the LAPD BolaWrap pilot program, which demonstrated that the BolaWrap was ineffective, expensive, and sparingly used in the field; and (2) as a result, Defendants’ public statements were materially false and/or misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

If you wish to serve as lead plaintiff, you must move the Court no later than November 23, 2020. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

No class has been certified. Until a class is certified, you are not represented by counsel unless you hire one. You may hire counsel of your choice. You may also do nothing at this time and be an absent member of the class. Your ability to share in any future recovery is not dependent upon being a lead plaintiff.

Pawar Law Group represents investors from around the world. Attorney advertising. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
——————————-

Contact:
Vik Pawar, Esq.
Pawar Law Group
20 Vesey Street, Suite 1410
New York, NY 10007
Tel: (917) 261-2277
Fax: (212) 571-0938
[email protected]

OSS Reports Q3 2020 Revenue up 12% to $13.0 Million Sequentially, Driving Net Income to $858,000 or $0.05 per Share

ESCONDIDO, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) — One Stop Systems, Inc. (Nasdaq: OSS), a leader in specialized high-performance edge computing, reported results for the third quarter and nine months ended September 30, 2020. All quarterly and first nine-month comparisons are to the same year-ago period unless otherwise noted.

Q3
2020
Financial
Highlights

  • Revenue totaled $13.0 million, up 12% sequentially from Q2 2020, and was lower by 13% versus the same year-ago quarter due to COVID-19-related issues.
  • Gross profit margin improved to 37.8% from 28.6% in Q2 2020 and 33.7% in Q3 2019.
  • Operating expenses decreased 15% from the year-ago quarter to $3.9 million.
  • Net income was up 57% to $858,000 or $0.05 per share.
  • Non-GAAP net income increased 38% to $1.2 million or $0.07 per share (see definition of this and other non-GAAP measures and reconciliation to GAAP, below).
  • Adjusted EBITDA, a non-GAAP term, increased 50% to $1.6 million from $1.0 million.
  • Cash and cash equivalents totaled $5.5 million at September 30, 2020, up from $4.7 million at June 30, 2020, with current cash balances of approximately $5.4 million.

First Nine Months
2020
Financial
Highlights

  • Revenue was $38.0 million, lower by 5% due to COVID-19-related issues.
  • Operating expenses decreased 19% to $12.6 million.
  • Loss from operations improved by $1.7 million to $938,000.
  • Net loss on a GAAP basis totaled $250,000 or $(0.02) per basic and diluted share, improving from a net loss of $2.0 million or $(0.13) per basic and diluted share. On a proforma basis, after giving effect to an adjustment for a goodwill impairment charge in the prior year, the change in net loss was basically flat compared to the same prior year period.
  • Non-GAAP net income totaled $773,000 or $0.05 per share, compared to non-GAAP net income of $1.0 million or $0.06 per diluted share.

Q3
2020 Operational Highlights

  • Received two purchase orders totaling $4.3 million for OSS mil-spec data storage units based on the existing $36 million, five-year supplier agreement for an airborne military radar application.
  • Won four new major programs, including industrial, medical and two new military programs for edge computing. Brought total wins so far this year to 13, one less than at this point last year, despite the impact of the pandemic.
  • Further reduced operating expenses by more than $1.2 million, keeping the company on track for a target of $2.5 million to $3 million in reduced operating costs on an annual basis.

Q3
Financial Summary

Revenue in the third quarter of 2020 totaled $13.0 million, up 12% from $11.6 million in the previous quarter and lower by 13% compared to $14.9 million in the same year-ago quarter. The sequential improvement in the third quarter of 2020 was due to increased military related sales. The decrease compared to the year-ago quarter was primarily due to the company’s media and entertainment business being lower by approximately $1.8 million because of issues related to the COVID-19 pandemic. This industry is expected to be impacted well into 2021.

In the third quarter of 2020, OSS core business contributed $9.0 million of revenue as compared to $9.7 million of revenue in the same year-ago period. The company’s Bressner subsidiary contributed $4.0 million of revenue in the third quarter of 2020, a decrease compared to $5.2 million of revenue in the same year-ago quarter.

Gross profit in the third quarter of 2020 was $4.9 million or 37.8% of revenue, representing an improvement in gross margin percentage compared to $5.0 million or 33.7% of revenue in the same year-ago quarter.

Gross margin for the company’s core OSS business increased to 44.6% in the third quarter of 2020 from 39.0% in the same year-ago quarter, which was attributed to higher margin military sales combined with a decrease of the lower margin media and entertainment business. Bressner’s gross margin decreased to 22.5% in the third quarter of 2020, as compared to 23.7% in the same year-ago quarter.

Operating expenses in Q3 decreased 15% to $3.9 million compared to $4.6 million in the same year-ago quarter. Operating expenses as a percentage of revenue improved to 30.2% in Q3 2020 versus 30.9% in the year-ago quarter. The decrease was primarily due to the cost reduction initiative the company began in April, when it reduced its workforce and new cost containment efforts were implemented.

Net income on a GAAP basis totaled $858,000 or $0.05 per share in Q3 2020 compared to a net income of $545,000 or $0.03 per share in the year-ago period.

Non-GAAP net income increased to $1.2 million or $0.07 per share in Q3, as compared to $901,000 or $0.05 per diluted share in the same year-ago period.

Adjusted EBITDA, a non-GAAP term, improved to $1.6 million in Q3, as compared to $1.0 million in the same year-ago period.

Cash and cash equivalents totaled $5.5 million as of September 30, 2020, as compared to $4.7 million at June 30, 2020. The company believes its cash position and other available funds provide it with sufficient liquidity to meet its cash requirements for current operations.

First
Nine Month
of 2020
Financial Summary

For the first nine months of 2020, revenue was $38.0 million, a decrease of 5% from $39.9 million in the same year-ago period. The decrease was primarily due to $3.8 million in lower revenue from a media and entertainment customer, which was attributed to COVID-related issues. This decrease was partially offset by growth of new business from the U.S. Navy, autonomous vehicles customers, and PCIe-Gen 4 test equipment suppliers, which totaled $5.9 million.

OSS core business contributed revenue of $24.7 million in the first nine months of 2020, a decrease of 6% from $26.2 million in the same year-ago period. Bressner contributed revenue of $13.2 million, down from $13.7 million in the same year-ago period.

Gross profit was $11.6 million or 30.6% of revenue in the first nine months of 2020, compared to $12.9 million or 32.2% of revenue in the same year-ago period.

Gross margin for the company’s core OSS business declined to 35.7% in the first nine months of 2020 from 37.2% in the same year-ago period, which was attributable to the reduction of sales and change in product mix as compared to the same year-ago period. Bressner’s gross margin decreased to 21.1% in the first nine months of 2020, as compared to 22.8% in the same year-ago period.

Operating expenses decreased 19% to $12.6 million in first nine months of 2020 from $15.4 million in the same year-ago period. Operating expenses as a percentage of revenue improved to 33.1% versus 38.7% in the year-ago period. On a pro forma basis, after adjusting for the prior year nine months goodwill impairment charge of $1.7 million, operating expenses decreased 8.6% to $12.3 million as compared to the same prior year period. This lower expense level reflects the $2.5 million to $3.0 million in anticipated annual savings resulting from the expense reduction program.

Net loss on a GAAP basis totaled $250,000 or $(0.02) per share in the first nine-month period of 2020, as compared to a loss of $2.0 million or $(0.13) per share in the first nine months of 2019. On a proforma basis, after giving effect to the goodwill impairment charge in the prior year, the change in net loss was relatively flat versus the prior year.

Non-GAAP net income totaled $773,000 or $0.05 per share, as compared to non-GAAP net income of $1.0 million or $0.06 per diluted share in the first nine months of 2019.

Adjusted EBITDA, a non-GAAP term, was $682,000 in the first nine months of 2020, as compared to $881,000 in the same year-ago period.

Management Commentary

“In Q3, we exceeded our minimum revenue guidance of $11.8 million, coming in at $13 million,” said OSS president and CEO, David Raun. “We also strengthened our gross margins to 37.8%, compared to 28.6% in the previous quarter and 33.7% in the same year-ago quarter. This helped drive net income up 57% to $858,000 or $0.05 per share.

“During the third quarter, we also further improved efficiency and strengthened our operations for both the near and long term. So far this year we have reduced operating expenses by more than $1.2 million and we remain on track for our targeted $2.5 million to $3 million in reduced costs on an annual basis.

“On the new product front, we recently expanded our PCI Express Gen 4 product line with the 4U Pro, a professional expansion platform that delivers twice the high-performance edge computing performance of our popular Gen 3 products. For this industry-leading solution, we are seeing strong customer interest from industry leaders in instrumentation, measurement, factory automation, automotive, military and other edge computing markets. One of our first shipments of the 4U Pro will be for the world’s largest composable high-performance computer being developed by one of our customers for the U.S. Army.

“Such new product introductions have helped our opportunity pipeline to continue to grow. During the quarter, we closed four additional major opportunities, including industrial, medical and two new military programs in edge computing. This brings the total to 13 program wins so far this year, compared to 14 wins this time last year despite the headwinds of the pandemic.

“While this quarter continued to be challenging for OSS and many of our customers, we made significant progress in multiple areas that positioned us for strengthened performance ahead. This includes diversifying our customer base, new product development, greater efficiency, lower operating expenses, improved profitability and a healthier balance sheet.”  

Outlook

For the fourth quarter of 2020, OSS expects revenue of approximately $13.0 million, with similar gross margins compared to the previous quarter.

Conference Call

OSS management will hold a conference call to discuss its third quarter 2020 results later today, followed by a question-and-answer period.

Date: Thursday, November 12, 2020
Time: 5:00 p.m. Eastern time (2:00 p.m. Pacific time)
Toll-free dial-in number: 1-800-430-8332
International dial-in number: 1-786-204-3966
Conference ID: 2953831

The conference call will be webcast live and available for replay here as well as via a link in the Investors section of the company’s website at ir.onestopsystems.com. OSS regularly uses its website to disclose material and non-material information to investors, customers, employees and others interested in the company.

Please call the conference telephone number five minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact CMA at 1-949-432-7566.

A replay of the call will be available after 8:00 p.m. Eastern time on the same day through November 26, 2020.

Toll-free replay number: 1-844-512-2921
International replay number: 1-412-317-6671
Replay ID: 2953831

About One Stop Systems

One Stop Systems, Inc. (OSS) designs and manufactures innovative specialized high-performance edge computing modules and systems, including customized servers, compute accelerators, expansion systems, flash storage arrays and Ion Accelerator storage software. These products are used for deep learning, AI, defense, finance, and entertainment applications, and empower scientists, engineers, creators and other professionals to push the boundaries of their industries.

OSS utilizes the power of PCI Express, the latest GPU accelerators and NVMe storage to build award-winning systems, including many industry firsts, for OEMs and government customers. The company enables AI on the Fly® by bringing AI datacenter performance to ‘the edge’ and on mobile platforms, and by addressing the entire AI workflow, from high speed data acquisition to deep learning, training and inference. OSS products are available directly or through global distributors. For more information, go to www.onestopsystems.com.

Non-GAAP Financial Measures

Management believes that the use of adjusted earnings before interest, taxes, depreciation and amortization, or adjusted EBITDA, is helpful for an investor to assess the performance of the Company. The Company defines adjusted EBITDA as income (loss) attributable to common stockholders before interest, taxes, depreciation, amortization, acquisition expenses, impairment of long-lived assets, financing costs, fair value adjustments from purchase accounting, stock-based compensation expense and expenses related to discontinued operations.

Adjusted EBITDA is not a measurement of financial performance under generally accepted accounting principles in the United States, or GAAP. Because of varying available valuation methodologies, subjective assumptions and the variety of equity instruments that can impact a company’s non-cash operating expenses, management believes that providing a non-GAAP financial measure that excludes non-cash and non-recurring expenses allows for meaningful comparisons between the company’s core business operating results and those of other companies, as well as providing the company with an important tool for financial and operational decision making and for evaluating its core business operating results over different periods of time.

The company’s adjusted EBITDA measure may not provide information that is directly comparable to that provided by other companies in the same industry, as other companies in the same industry may calculate non-GAAP financial results differently, particularly related to non-recurring, unusual items. The company’s adjusted EBITDA is not a measurement of financial performance under GAAP, and should not be considered as an alternative to operating income or as an indication of operating performance or any other measure of performance derived in accordance with GAAP. Management does not consider adjusted EBITDA to be a substitute for, or superior to, the information provided by GAAP financial results.

    For the Three Months

Ended September 30,
    For the Nine Months

Ended September 30,
 
    2020     2019     2020     2019  
Net income (loss) attributable to common stockholders   $ 857,790     $ 544,901     $ (250,404 )   $ (1,994,461 )
Depreciation and amortization     410,552       352,905       1,208,762       1,239,887  
Amortization of deferred gain           (12,359 )     (53,838 )     (45,316 )
Impairment of goodwill                       1,697,394  
Stock-based compensation expense     210,280       164,857       503,419       490,140  
Interest income     (143,931 )     (10,149 )     (267,911 )     (23,424 )
Interest expense     174,205       52,182       393,175       111,463  
Provision (benefit) for income taxes     57,753       (51,051 )     (851,056 )     (594,890 )
Adjusted EBITDA   $ 1,566,649     $ 1,041,286     $ 682,147     $ 880,793  

Adjusted EPS excludes the impact of certain items and, therefore, has not been calculated in accordance with GAAP. Management believes that exclusion of certain selected items assists in providing a more complete understanding of the underlying results and trends and allows for comparability with the company’s peer company index and industry. Management uses this measure along with the corresponding GAAP financial measures to manage the business and to evaluate the company’s performance compared to prior periods and the marketplace. The Company defines Non-GAAP (loss) income attributable to common stockholders as (loss) or income before amortization, stock-based compensation, expenses related to discontinued operations, impairment of long-lived assets and non-recurring acquisition costs. Adjusted EPS expresses adjusted (loss) income on a per share basis using weighted average diluted shares outstanding.

Adjusted EPS is a non-GAAP financial measure and should not be considered in isolation or as a substitute for financial information provided in accordance with GAAP. These non-GAAP financial measures may not be computed in the same manner as similarly titled measures used by other companies. Management expects to continue to incur expenses similar to the adjusted income from continuing operations and adjusted EPS financial adjustments described above, and investors should not infer from the company’s presentation of these non-GAAP financial measures that these costs are unusual, infrequent or non-recurring.

The following table sets-forth non-GAAP net loss attributable to common stockholders and basic and diluted earnings per share:

    For The Three Months

Ended September 30,
    For The Nine Months

Ended September 30,
 
    2020     2019     2020     2019  
Net income (loss) attributable to common stockholders   $ 857,790     $ 544,901     $ (250,404 )   $ (1,994,461 )
Amortization of intangibles     170,985       190,970       520,035       809,540  
Impairment of goodwill                       1,697,394  
Stock-based compensation expense     210,280       164,857       503,419       490,140  
Non-GAAP net income attributable to common stockholders   $ 1,239,055     $ 900,728     $ 773,050     $ 1,002,613  
                                 
Non-GAAP net income per share attributable to common stockholders:                                
Basic   $ 0.07     $ 0.06     $ 0.05     $ 0.07  
Diluted   $ 0.07     $ 0.05     $ 0.05     $ 0.06  
Weighted average common shares outstanding:                                
Basic     16,585,773       15,777,158       16,469,457       14,825,351  
Diluted     17,018,614       16,390,206       16,902,298       15,438,400  

Forward-Looking Statements

One Stop Systems cautions you that statements in this press release that are not a description of historical facts are forward-looking statements. These statements are based on the company’s current beliefs and expectations. The inclusion of forward-looking statements should not be regarded as a representation by One Stop Systems or its partners that any of our plans or expectations will be achieved, including but not limited to, to our management’s expectations for revenue growth generated by new products and design wins. Actual results may differ from those set forth in this press release due to the risk and uncertainties inherent in our business, including risks described in our prior press releases and in our filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in our Annual Report on Form 10-K and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and we undertake no obligation to revise or update this press release to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Media Contact:

Katie Rivera
One Stop Systems, Inc.
Tel (760) 745-9883
Email contact

Investor Relations:

Ronald Both or Grant Stude
CMA
Tel (949) 432-7557
Email contact

ONE STOP SYSTEMS, INC. (OSS)

UNAUDITED CONSOLIDATED B
ALANCE SHEETS

    September 30,     December 31,  
    2020     2019  
ASSETS                
Current assets                
Cash and cash equivalents   $ 5,519,829     $ 5,185,321  
Accounts receivable, net     9,744,171       11,667,157  
Inventories, net     9,999,680       7,369,356  
Prepaid expenses and other current assets     720,070       453,938  
Total current assets     25,983,750       24,675,772  
Property and equipment, net     3,567,582       3,568,564  
Deposits and other     81,711       47,146  
Deferred tax assets, net     3,939,546       3,019,823  
Goodwill     7,120,510       7,120,510  
Intangible assets, net     826,157       1,346,192  
    $ 41,519,256     $ 39,778,007  
                 
LIABILITIES AND STOCKHOLDERS’ EQUITY                
Current liabilities                
Accounts payable   $ 3,680,192     $ 4,115,977  
Accrued expenses and other liabilities     3,758,109       4,607,432  
Current portion of notes payable, net of debt discount of $3,802 and $7,019, respectively     1,433,200       1,377,751  
Current portion of related-party notes payable, net of debt discount of $12,491 and $23,060, respectively     345,586       561,441  
Senior secured convertible note, net of discounts of $337,247     1,299,117        
Total current liabilities     10,516,204       10,662,601  
Notes payable, net of current portion and debt discount of $0 and $2,047, respectively           149,301  
Related-party notes payable, net of current portion and debt discount of $0 and $6,726, respectively           199,943  
Senior secured convertible note, net of discounts of $51,707     902,839        
Paycheck protection plan note payable     1,499,360        
Total liabilities     12,918,403       11,011,845  
Commitments and contingencies                
Stockholders’ equity                
Common stock, $.0001 par value; 50,000,000 shares authorized; 16,620,908 and 16,121,747 shares issued and outstanding, respectively     1,662       1,612  
Additional paid-in capital     30,480,405       30,537,015  
Noncontrolling interest           500  
Accumulated other comprehensive loss     124,382       (17,773 )
Accumulated deficit     (2,005,596 )     (1,755,192 )
Total stockholders’ equity     28,600,853       28,766,162  
    $ 41,519,256     $ 39,778,007  
 
 

ONE STOP SYSTEMS, INC. (OSS)

UNAUDITED CONSOLIDATED STATEM
ENTS OF OPERATIONS

    For the Three Months Ended
September 30,
    For the Nine Months Ended
September 30,
 
    2020     2019     2020     2019  
Revenue   $ 12,976,058     $ 14,938,964     $ 37,961,023     $ 39,883,099  
Cost of revenue     8,074,445       9,909,045       26,338,527       27,028,399  
Gross profit     4,901,613       5,029,919       11,622,496       12,854,700  
Operating expenses:                                
General and administrative     1,817,499       2,190,003       6,208,922       6,468,021  
Impairment of goodwill                       1,697,394  
Marketing and selling     1,103,384       1,383,965       3,137,833       3,758,901  
Research and development     1,001,288       1,036,394       3,213,339       3,523,515  
Total operating expenses     3,922,171       4,610,362       12,560,094       15,447,831  
Income (loss) from operations     979,442       419,557       (937,598 )     (2,593,131 )
Other income (expense):                                
Interest income     143,931       10,149       267,911       23,424  
Interest expense     (174,205 )     (52,182 )     (393,175 )     (111,463 )
Other income (expense), net     (33,625 )     116,326       (38,598 )     91,819  
Total other income (expense), net     (63,899 )     74,293       (163,862 )     3,780  
Income (loss) before income taxes     915,543       493,850       (1,101,460 )     (2,589,351 )
Provision (benefit) for income taxes     57,753       (51,051 )     (851,056 )     (594,890 )
Net income (loss) attributable to common stockholders   $ 857,790     $ 544,901     $ (250,404 )   $ (1,994,461 )
                                 
Net income (loss) per share attributable to common stockholders:                                
Basic   $ 0.05     $ 0.03     $ (0.02 )   $ (0.13 )
Diluted   $ 0.05     $ 0.03     $ (0.02 )   $ (0.13 )
                                 
Weighted average common shares outstanding:                                
Basic     16,585,773       15,777,158       16,469,457       14,825,351  
Diluted     17,018,614       16,390,206       16,469,457       14,825,351  

SHAREHOLDER DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against Reata Pharmacceuticals, Inc.– RETA; IMPORTANT DEADLINE –RETA

NEW YORK, Nov. 12, 2020 (GLOBE NEWSWIRE) — Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) from October 15, 2019 through August 7, 2020, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Reata Pharmaceuticals, Inc. investors under the federal securities laws.

To join the class action, go here or call Vik Pawar, Esq. toll-free at 888-589-9804 or email [email protected] for information on the class action.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) the MOXIe Part 2 study results were insufficient to support a single study marketing approval of omaveloxolone for the treatment of Friedreich’s ataxia (“FA”) in the U.S. without additional evidence; (2) as a result, it was foreseeably likely that the FDA would not accept marketing approval of omaveloxolone for the treatment of FA in the U.S. based on the MOXIe Part 2 study results; and (3) as a result, the Company’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages..

If you wish to serve as lead plaintiff, you must move the Court no later than December 14, 2020. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

No class has been certified. Until a class is certified, you are not represented by counsel unless you hire one. You may hire counsel of your choice. You may also do nothing at this time and be an absent member of the class. Your ability to share in any future recovery is not dependent upon being a lead plaintiff.

Pawar Law Group represents investors from around the world. Attorney advertising. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
——————————-

Contact:  
Vik Pawar, Esq.  
Pawar Law Group  
20 Vesey Street, Suite 1410  
New York, NY 10007  
Tel: (917) 261-2277  
Fax: (212) 571-0938  
[email protected]  

Sierra School of Gilbert Expands Services With Opening of Adult Day Program

Focus on Purposeful Activities and Enhancing Daily Living Skills for Young Adults 18-26 Who Are Exiting School Services

GILBERT, Ariz., Nov. 12, 2020 (GLOBE NEWSWIRE) — Specialized Education Services, Inc. (SESI), a premier provider of education services for K-12 students who require additional educational and positive behavioral supports, announced the opening of its Adult Day Program (DTA) at the Sierra School of Gilbert. The program, which serves young adults (ages 18-26) with developmental disabilities, centers on recreational activities with an emphasis on community integration. Approved by the Arizona Division of Developmental Disabilities (DDD/DES), the DTA program provides a resource for those who are exiting school services.

When an individual enrolls, their programmatic goals are personally designed. Staff provide coaching that expands members’ repertoire of essential skills in areas like community knowledge, social awareness, personal organization, basic communication and leisure activities. Each member is encouraged to participate to their full potential in a supportive space that embraces community, friendship, and neurodiversity.

“We are excited to offer the program as an opportunity for young adults who are not headed to traditional post-secondary options but want to stay active and continue learning in a supportive space,” said Jessica Mayfield, Director of Clinical and Specialty Services, Sierra School of Gilbert. “Our expert staff can support these individuals with mastering life skills in an environment that also encourages socialization and having fun.”

The DTA program runs Monday-Friday from 8 a.m. to 3 p.m. and is currently accepting new members, with priority given to former Sierra School students. Members from the broader community are also invited to learn more about the program. Transportation to the program is available for members living within a 10-mile radius of the campus (875 South Cooper Road, Gilbert). For more information on services and enrollment, visit: https://sesischools.com/locations/arizona/sierra-school-of-gilbert/.

About Specialized Education Services, Inc. 

Specialized Education Services, Inc. (SESI), a division of FullBloom, is a premier provider of education services for K-12 students who require additional educational and positive behavioral supports to overcome challenges that impede success in a traditional school setting. SESI partners with school districts to offer professional development and to run in-district classrooms and stand-alone schools that meet the academic, behavioral, social, and emotional needs of special and alternative education students with Autism Spectrum Disorders, Learning, Emotional and other disabilities. Implementing a signature, research-based education model that incorporates supportive therapies, life skills training, and workforce development programs, as well as professional learning for special education teachers, SESI guides students toward success in and out of the classroom. It proudly serves over 3,000 students through over 50 day schools and 80+ in-district classrooms and partners with over 500 school districts. SESI is accredited by Cognia (formerly AdvancED). www.sesischools.com.

Press Contact 
Jennifer Leckstrom
RoseComm for SESI 
(215) 681-0770
[email protected]

SHAREHOLDER DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against Precigen, Inc. f/k/a Intrexon- PGEN, XON; IMPORTANT DEADLINE –Precigen, Inc. f/k/a Intrexon Corporation– PGEN, XON

NEW YORK, Nov. 12, 2020 (GLOBE NEWSWIRE) — Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Precigen, Inc. f/k/a (NASDAQ: PGEN, XON) from May 10, 2017  through September 25, 2020, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Precigen, Inc. f/k/a Intrexon Corporation investors under the federal securities laws.

To join the class action, go here or call Vik Pawar, Esq. toll-free at 888-589-9804 or email [email protected] for information on the class action.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that:  (1) the Company was using pure methane as feedstock for its announced yields for its methanotroph bioconversion platform instead of natural gas; (2) yields from natural gas as a feedstock were substantially lower than the aforementioned pure methane yields; (3) due to the substantial price difference between pure methane and natural gas, pure methane was not a commercially viable feedstock; (4) the Company’s financial statements for the quarter ended March 31, 2018 were false and could not be relied upon; (5) the Company had material weaknesses in its internal controls over financial reporting; (6) the Company was under investigation by the SEC since October 2018; and (7) as a result of the foregoing, defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

If you wish to serve as lead plaintiff, you must move the Court no later than December 4, 2020. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

No class has been certified. Until a class is certified, you are not represented by counsel unless you hire one. You may hire counsel of your choice. You may also do nothing at this time and be an absent member of the class. Your ability to share in any future recovery is not dependent upon being a lead plaintiff.

Pawar Law Group represents investors from around the world. Attorney advertising. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact:  
Vik Pawar, Esq.  
Pawar Law Group  
20 Vesey Street, Suite 1410  
New York, NY 10007  
Tel: (917) 261-2277  
Fax: (212) 571-0938  
[email protected]  

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Akers Biosciences, Inc.

PR Newswire

NEW YORK, Nov. 12, 2020 /PRNewswire/ — Rowley Law PLLC is investigating potential securities law violations by Akers Biosciences, Inc. (NASDAQ: AKER) and its board of directors concerning the proposed merger of the company with MyMD Pharmaceuticals, Inc. Akers Biosciences stockholders will own 20% of the combined company. The transaction is expected to close in the first half of 2021.

If you are a stockholder of Akers Biosciences, Inc. and are interested in obtaining additional information regarding this investigation, please visit us at: http://www.rowleylawpllc.com/investigation/aker/. You may also contact Shane Rowley, Esq. at Rowley Law PLLC, 50 Main Street Suite 1000, White Plains, NY 10606, by email at [email protected], or by telephone at 914-400-1920 or 844-400-4643 (toll-free).  

Rowley Law PLLC represents shareholders nationwide in class actions and derivative lawsuits in complex corporate litigation. For more information about the firm and its attorneys, please visit http://www.rowleylawpllc.com

Attorney Advertising. Prior results do not guarantee a similar outcome.

Cision View original content:http://www.prnewswire.com/news-releases/alert-rowley-law-pllc-is-investigating-proposed-acquisition-of-akers-biosciences-inc-301172322.html

SOURCE Rowley Law PLLC

Vuzix Continues to Receive Multiple Follow-On M400 Smart Glasses Orders from Both Resellers and End Customers to Support Business Operations Amid COVID-19 Pandemic

– A Fortune 500 engine manufacturer and a pharmaceutical air transportation solution provider place follow-on orders

– Brochesia places a follow-on order to support industrial production, construction, transportation and marine customers

PR Newswire

ROCHESTER, N.Y., Nov. 12, 2020 /PRNewswire/ — Vuzix® Corporation (NASDAQ: VUZI), (“Vuzix” or, the “Company”), a leading supplier of Smart Glasses and Augmented Reality (AR) technology and products, today announced that the Company has received initial follow-on orders and delivered M400 Smart Glasses kits to support remote support and training after rapid and successful proof of concept evaluations were performed by two new customers. The COVID-19 global pandemic continues to be an accelerant for the adoption within the enterprise smart glasses.

The first customer is a Fortune 500 engine manufacturer and distributor and after a rapid and successful proof of concept evaluation was completed this summer using a hand full of M400 Smart Glasses to support technicians with remote guidance and training, the customer placed a follow-on order that was recently delivered for broader deployment of M400 Smart Glasses. 

The second company is leading global provider of pharmaceutical air transportation solutions and after a rapid and successful proof of concept evaluation using one M400 Smart Glasses to support technicians with remote guidance and training, the company placed a follow-on order for many more M400 Smart Glasses that was recently delivered. 

“Over the last few quarters, we have witnessed many customers both large and small within the enterprise smart glasses industry moving faster between pilot evaluation and volume deployments into their operations.  These two customers are proof points and prime examples of how Vuzix Smart Glasses are being effective out of the box to deliver remote guidance and training to provide sizable benefits for our customers,” said Paul Travers, Vuzix President and Chief Executive Officer. “We look forward to supporting these customers as they continue to deploy Vuzix Smart Glasses across their operations.”

In addition to these two direct customers, Vuzix also received a follow-on M400 Smart Glasses order (unit total not disclosed due to competitive reasons) from Brochesia, a software solution provider based in Italy that  sells smart glasses based solution into enterprise to support manufacturing, healthcare, field service and logistics.

After successfully piloting the Vuzix M400 Smart glasses, Brochesia will be delivering devices to enterprise end customers to be deployed in support of industrial production, construction, transportation and the marine industry. 

“The Vuzix M400 Smart Glasses powered by the Brochesia software suite have been well received by our customers and we are pleased to see them moving from forward from pilots to production,” commented Claudia Simon, Chief Operating Officer of Brochesia.

“The Brochesia software platform with the Vuzix M400 Smart Glasses are being put to work across multiple enterprise verticals,” said Paul Travers, Vuzix President and Chief Executive Officer. “Vuzix looks forward to supporting Brochesia’s as they continue to roll out their Vuzix Smart Glasses-based solution across their extensive customer base.”

About Vuzix Corporation

Vuzix is a leading supplier of Smart-Glasses and Augmented Reality (AR) technologies and products for the consumer and enterprise markets. The Company’s products include personal display and wearable computing devices that offer users a portable high-quality viewing experience, provide solutions for mobility, wearable displays and augmented reality. Vuzix holds 179 patents and patents pending and numerous IP licenses in the Video Eyewear field. The Company has won Consumer Electronics Show (or CES) awards for innovation for the years 2005 to 2020 and several wireless technology innovation awards among others. Founded in 1997, Vuzix is a public company (NASDAQ: VUZI) with offices in Rochester, NY, Oxford, UK, and Tokyo, Japan. For more information, visit Vuzix websiteTwitter and Facebook pages.

Forward-Looking Statements Disclaimer

Certain statements contained in this news release are “forward-looking statements” within the meaning of the Securities Litigation Reform Act of 1995 and applicable Canadian securities laws. Forward looking statements contained in this release relate to the Vuzix Smart Glasses, our business opportunities with the above mentioned firms, along the ultimate success and future business opportunities with these firms, and among other things the Company’s leadership in the Smart Glasses and AR display industry. They are generally identified by words such as “believes,” “may,” “expects,” “anticipates,” “should” and similar expressions. Readers should not place undue reliance on such forward-looking statements, which are based upon the Company’s beliefs and assumptions as of the date of this release. The Company’s actual results could differ materially due to risk factors and other items described in more detail in the “Risk Factors” section of the Company’s Annual Reports and MD&A filed with the United States Securities and Exchange Commission and applicable Canadian securities regulators (copies of which may be obtained at www.sedar.com or www.sec.gov). Subsequent events and developments may cause these forward-looking statements to change. The Company specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law.

Media and Investor Relations Contact:

Ed McGregor, Director of Investor Relations, Vuzix Corporation [email protected] Tel: (585) 359-5985

Vuzix Corporation, 25 Hendrix Road, Suite A, West Henrietta, NY 14586 USA,
Investor Information – [email protected]www.vuzix.com

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/vuzix-continues-to-receive-multiple-follow-on-m400-smart-glasses-orders-from-both-resellers-and-end-customers-to-support-business-operations-amid-covid-19-pandemic-301172313.html

SOURCE Vuzix Corporation

HighPoint Partners with UiPath to Improve Citizen Experiences through Automation

Partnership enables government agencies to achieve operational effectiveness and improve customer experiences through RPA

HERNDON, Va., Nov. 12, 2020 (GLOBE NEWSWIRE) — HighPoint, a provider of IT and digital services for government agencies, announced today that it is partnering with robotic process automation (RPA) software provider, UiPath, to automate high-volume, repetitive processes that will improve government efficiency and customer experiences.

Through this partnership, HighPoint will help government agencies implement RPA to build more efficient, streamlined, and responsive organizations, while driving innovation and achieving digital transformation objectives. HighPoint will bring its experience with large-scale government contact centers and high-volume repositories to identify areas of improvement, reduce redundancies, and improve productivity and customer experience. HighPoint understands the evolution of today’s contact centers and will help agencies digitally evolve by leveraging emerging technologies, tools, and processes.

UiPath has a vision to deliver A Robot for Every Person, one where companies enable every employee to use, create, and benefit from the transformative power of automation to liberate the boundless potential of people. Only UiPath offers an end-to-end platform for automation, combining the leading RPA solution with a full suite of capabilities, including process mining and analytics, that enable every organization to scale digital business operations at unprecedented speed.

HighPoint also launched an Intelligent Automation Center of Excellence (CoE), which will be led by John Cyrus, Director of Emerging Technologies and IT Strategy. Prior to joining HighPoint, John Cyrus was the co-lead of the RPA CoE at the U.S. Patent and Trademark Office.

“HighPoint is committed to making information more available for government agencies and the people they serve,” said Cyrus. “We are excited to partner with UiPath to bring our clients innovation that will increase efficiency, accelerate digital transformation goals, and improve citizen and employee experiences.”

About HighPoint

HighPoint helps government agencies elevate customer and employee experiences. From contact centers and training to digital and data services, our team works with government agencies to more efficiently integrate the people, processes and technology that help government deliver on the needs of citizens and employees. HighPoint delivers services for 13 government clients including the Centers for Medicare and Medicaid Services, Office of the Comptroller of Currency, Department of State, Defense Logistics Agency and Department of Housing and Urban Development.

HighPoint is a privately held company founded in 2006 with employees across offices in Indianapolis, Indiana; Baltimore, Maryland; and Herndon, Virginia. To learn more, visit highpointglobal.com.

Contact:
Kim Miller
Director, Marketing and Communications
[email protected]

 

Twist Bioscience, Illumina and Western Digital Form Alliance with Microsoft to Advance Data Storage in DNA

Twist Bioscience, Illumina and Western Digital Form Alliance with Microsoft to Advance Data Storage in DNA

— Ten Additional Technology Leaders Join Founding Members to Together Advance Industry Roadmap, Set Stage for Widespread Adoption of New Long-term Storage Option —

— Announcement at Flash Memory Summit —

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Twist Bioscience Corporation (NASDAQ: TWST), Illumina, Inc. (NASDAQ: ILMN) and Western Digital (NASDAQ: WDC) today announced the formation of an alliance with Microsoft to advance the field of DNA data storage. These founding companies, alongside member organizations, will work together to create a comprehensive industry roadmap that will help the industry achieve interoperability between solutions and help establish the foundations for a cost-effective commercial archival storage ecosystem for the explosive growth of digital data.

“DNA is an incredible molecule that, by its very nature, provides ultra-high-density storage for thousands of years,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. “By joining with other technology leaders to develop a common framework for commercial implementation, we drive a shared vision to build this new market solution for digital storage.”

DNA data storage has the potential to deliver a true low-cost archival data storage solution. While current storage technologies have limited longevity and require data migration for long-term data storage, DNA provides a stable format storage medium that is durable for thousands of years when properly stored. In addition, DNA enables cost effective and rapid duplication. Importantly, it is incredibly dense, with 10 full length digital movies fitting into a volume the size of a single grain of salt. Digital data stored in DNA can be stored in a variety of containers including capsules, pellets or encased in glass beads.

“At Microsoft Research, we proactively address the future challenges of technology, with sustainability in mind,” commented Karin Strauss, Ph.D., senior principal research manager at Microsoft. “In collaboration with University of Washington, we have demonstrated a fully automated end-to-end system capable of storing and retrieving data from DNA, and we have separately stored 1GB of data in DNA synthesized by Twist and recovered data from it. We’re encouraged by the potential for more sustainable data storage with DNA and look forward to collaborating with others in the industry to explore early commercialization of this technology.”

By 2024, 30% of digital businesses will mandate DNA storage trials, addressing the exponential growth of data poised to overwhelm existing storage technology.1

“There is an unmet need for a new long-term archival storage medium that keeps up with the rate of digital data growth,” said Steffen Hellmold, vice president corporate strategic initiatives, Western Digital. “We estimate that almost half of the data storage solutions shipped in 2030 will be used to archive data as the overall temperature of data is cooling down. We are committed to providing a full portfolio of storage solutions addressing the demand for hot, warm and cold storage.”

“A key component of a DNA data storage system is its ability to read back the digital information when needed,” stated Alex Aravanis, M.D., Ph.D., chief technology officer at Illumina. “We believe Illumina’s innovative sequencing technology will be critical in enabling this market at commercial scale and look forward to collaborating with other leaders in their respective fields to make this a viable, long-term solution for archival storage.”

Twist Bioscience, Illumina, Western Digital and Microsoft are joining the Alliance as founding members. In addition to developing an industry roadmap, the DNA Data Storage Alliance plans to develop use cases in various markets and industries as well as promote and educate the larger storage community to promote adoption of this future solution. The following organizations have joined the alliance as members:

The Alliance welcomes additional participation from organizations within DNA and data storage industries that would like to contribute to this emerging ecosystem.

How to Store Digital Data in DNA

To store data in DNA, first, a data file is converted from its digital sequence of 0’s and 1’s into a DNA sequence of A’s, C’s, T’s and G’s. The DNA data file is then synthesized (“written”) in short segments of DNA (200 to 300 bases long) and stored. In addition to storing part of the data file, each short segment contains an index to indicate its place within the overall data file. To retrieve the data, the segments are sequenced (“read”) and then decoded back into the original file. One feature of the indexing system is it allows part of the file to be biologically recovered (“random access”) before sequencing, so only data of interest is sequenced. In addition, all data is recovered error-free because error-correcting algorithms are used during the encode/decode process. For a short video of the process watch: https://www.youtube.com/watch?v=LTnJWxCO3M4.

About Illumina

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. To learn more, visit www.illumina.com and connect with us on Twitter, Facebook, LinkedIn, Instagram, and YouTube.

About Western Digital

Western Digital creates environments for data to thrive. As a leader in data infrastructure, the company is driving the innovation needed to help customers capture, preserve, access and transform an ever-increasing diversity of data. Everywhere data lives, from advanced data centers to mobile sensors to personal devices, our industry-leading solutions deliver the possibilities of data. Our data-centric solutions are comprised of the Western Digital®, G-Technology™, SanDisk®, and WD® brands.

About Twist Bioscience Corporation

Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.

Follow us on Twitter | Facebook | LinkedIn | YouTube

Legal Notice Regarding Forward-Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical facts contained herein, including without limitation, the ability of the Alliance to advance DNA data storage, are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist Bioscience’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the risks and uncertainties of the ability to attract new customers and retain and grow sales from existing customers; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology could make the products Twist Bioscience is developing obsolete or non-competitive; scientific unknowns and new information relating to the SARS-CoV-2 virus; the duration, extent and impact of the COVID-19 pandemic; supply chain and other disruptions caused by the COVID-19 pandemic or otherwise; uncertainties of the retention of a significant customer; risks of third party claims alleging infringement of patents and proprietary rights or seeking to invalidate Twist Bioscience’s patents or proprietary rights; and the risk that Twist Bioscience’s proprietary rights may be insufficient to protect its technologies. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist Bioscience’s business in general, see Twist Bioscience’s risk factors set forth in Twist Bioscience’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 12, 2020. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Western Digital Forward-Looking Statements Disclaimer

This news release contains certain forward-looking statements, including expectations regarding the future applications, advances and success of DNA data storage and Western Digital’s expectations regarding its portfolio of storage solutions. There are a number of risks and uncertainties that may cause these forward-looking statements to be inaccurate including, among others: future responses to and effects of the COVID-19 pandemic; volatility in global economic conditions; impact of business and market conditions; impact of competitive products and pricing; our development and introduction of products based on new technologies and expansion into new data storage markets; risks associated with cost saving initiatives, restructurings, acquisitions, divestitures, mergers, joint ventures and our strategic relationships; difficulties or delays in manufacturing or other supply chain disruptions; hiring and retention of key employees; our high level of debt and other financial obligations; changes to our relationships with key customers; disruptions in operations from cyberattacks or other system security risks; actions by competitors; risks associated with compliance with changing legal and regulatory requirements and the outcome of legal proceedings; and other risks and uncertainties listed in Western Digital’s filings with the Securities and Exchange Commission (the “SEC”), including Western Digital’s Form 10-K filed with the SEC on August 28, 2020, to which your attention is directed. You should not place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Western Digital undertakes no obligation to update these forward-looking statements to reflect subsequent events or circumstances.

1Gartner Press Release, “Gartner Unveils Top Predictions for IT Organizations and Users in 2021 and Beyond”, October 21, 2020 https://www.gartner.com/en/newsroom/press-releases/2020-10-21-gartner-unveils-top-predictions-for-it-organizations-and-users-in-2021-and-beyond

Contacts for Twist Bioscience:

Investor Contact:

Argot Partners

Maeve Conneighton

212-600-1902

[email protected]

Media Contact:

Angela Bitting

925- 202-6211

[email protected]

Contacts for Western Digital

Media Contact:

Lisa Neitzel

1-408-717-7607

[email protected]

Investor Contact:

T. Peter Andrew

+1-949-672-9655

[email protected]

[email protected]

Contact for Illumina:

Dr. Karen Birmingham

1-646-355-2111

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Research Technology Security Genetics Software Biotechnology Pharmaceutical Health Data Management Science

MEDIA:

Logo
Logo